Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

In this decade a “bloom” of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targe...

詳細記述

書誌詳細

主要な著者:	Paul Zarogoulidis, Evaggelia Athanasiou, Theodora Tsiouda, Dimitrios Hatzibougias, Haidong Huang, Chong Bai, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Nikolaos Barbetakis, Dimitrios Paliouras, Aggeliki Rapti, Dimitrios Drougas, Wolfgang Hohenforst-Schmidt
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2017-01-01
シリーズ:	Respiratory Medicine Case Reports
主題:	Adenocarcinoma Lung cancer Immunotherapy Nivolumab Pembrolizumab Programmed death-ligand
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2213007117302733
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!